Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Paul Turnbull

- PMLiVE

Sanofi’s Sarclisa approved by MHRA as UK’s first anti-cancer treatment given via on-body injector

It is the first anticancer treatment in the UK and globally to be administered this way and a first in multiple myeloma

- PMLiVE

Pfizer appoints Cecile Guegan as Interim CFO

Guegan is currently the company’s Senior VP, Finance, Global Biopharmaceutical Business

- PMLiVE

Designing Pharma Stands That People Actually Want to Step Onto

Exhibition halls are busy environments where delegates move quickly, often with limited time. For pharmaceutical companies, this presents a challenge: how do you create a stand that invites meaningful engagement...

Apex Events and Exhibitions

- PMLiVE

Live Webinar | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026

Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

Inizio

- PMLiVE

The solution: Good localisation doesn’t feel translated

Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.

Cuttsy + Cuttsy

- PMLiVE

Good Patient Partnership Guide 2026: Patient Journey Mapping with the Patient Community

Patient insight gathering and journey mapping can inform and enhance decision making and initiatives across life sciences. The Good Patient Partnership Guide 2026 brings together practical guidance, real world examples...

Precision AQ

- PMLiVE

Healthcare information is becoming easier to access. Trust isn’t.

Sharing key insights from NEXT Pharma Summit on why trust, clarity and human-centred communication matter more than ever in healthcare.

Cuttsy + Cuttsy

It was never reluctance: What ASCO 2026 revealed about clinical trial recruitment

ASCO 2026 highlighted that low clinical trial recruitment is driven less by patient reluctance and more by gaps in awareness, communication, accessibility and patient education.

Cuttsy + Cuttsy

- PMLiVE

Takeda’s new study data for oveporexton shows improvements in narcolepsy type 1

The phase 3 results show improvements in daily function, cognition and nighttime sleep

- PMLiVE

Broken String Biosciences appoints Bruce Eaton as Chairman of the Board

Eaton specialises in strategic planning, organisational leadership and commercial execution

- PMLiVE

J‑Pharma Co., Ltd. and Uniphar Announce Advancement of Nanvuranlat into Phase 3 Clinical Development Following FDA Alignment and Initial Patient Enrollment

Strategic partnership enables direct progression to Phase 3, bypassing additional Phase 2 study, as first patients are randomized in global trial  TOKYO, Japan and DUBLIN, Ireland — [June 16, 2026] J‑Pharma Co., Ltd., a clinical-stage biotechnology...

Uniphar

- PMLiVE

Gilead’s New Drug Application for Yeztugo accepted by US FDA

The investigational once-weekly oral treatment could be the first long-acting pill for HIV prevention

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links